Skip to main content
Clinical Trials/NCT01298050
NCT01298050
Unknown
Not Applicable

Refractory In and Out of Hospital Cardiac Arrest Treated With Extracorporeal Membrane Oxygenation. Observational, Single Centre, Prospective Study.

University of Milano Bicocca1 site in 1 country40 target enrollmentJuly 2011
ConditionsCardiac Arrest

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiac Arrest
Sponsor
University of Milano Bicocca
Enrollment
40
Locations
1
Primary Endpoint
28 days survival
Last Updated
14 years ago

Overview

Brief Summary

Extracorporeal membrane oxygenation (ECMO) support has been suggested to improve the survival rate in patients with refractory cardiac arrest (CA). Recent studies have also highlighted the potential early application of this method in improving the prognosis of prolonged cardiac arrest both for in hospital CA (INHCA) and out of hospital CA (OHCA). The rationale for use of ECMO in these patients is to optimize early perfusion of vital organs, curing the cause of CA and waiting for the recovery of the injured myocardium. The investigators have created a flow-chart to decide which patients are eligible. The aims of this study are to evaluate if, with this flow-chart, the investigators are able to detect which patients have more probability of survival.

Registry
clinicaltrials.gov
Start Date
July 2011
End Date
July 2013
Last Updated
14 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Adults 18-75 years old
  • In and out of hospital Witnessed Cardiac Arrest
  • No-flow time \< 5 min. or VF,VT,TP as rhythm of presentation
  • Low-flow time \< 45 min.
  • End Tidal CO2 \> 10 after 20 min.of CPR

Exclusion Criteria

  • Comorbidities such:
  • Terminal Malignancy
  • Aortic Dissection
  • Severe Cardiac Failure without transplant indication
  • Severe Aortic Valve Failure
  • Known Severe Peripheral arteriopathy

Outcomes

Primary Outcomes

28 days survival

Time Frame: 28 days

Secondary Outcomes

  • Neurologic recovery(28 days)
  • Cardiac recovery(28 days)
  • Six months survival with minimal neurologic impairment(180 days)

Study Sites (1)

Loading locations...

Similar Trials